Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria

Main Article Content

Chimaobi Gideon Ofoha
Felix Echebiri Magnus

Abstract

Aims: To determine the presentation, characteristics and associated co-morbidities in Nigerian men with prostate cancer.

Study Design: Retrospective study.

Place and Duration of Study: The study was carried at the Division of Urology, Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria from January 2010 to December 2018.

Methodology: Men with histologically confirmed prostate cancer were analyzed. The age of the men, PSA pattern, histologic type, Gleason score, stage of the disease, associated co-morbidities and treatment received by the men were recorded. The effect of co-morbidities on disease aggressiveness using Gleason score and PSA as determinants was determined using Pearson correlation. SPSS version 23 was used in analyzing the data.  P-value of < 0.05 was considered significant.

Results: Eighty-one patients with prostate cancer from 2010 to 2018 were involved in the study. The mean age was 67.58±9.42 years with a range of 42 to 96years.  Men with PSA >100 ng/ml had the highest frequency (34.60%). The mean Gleason Score was 6.28±2.13. Gleason score 7-8 had the highest frequency (35.8%). Seventy-nine patients (97.5%) had adenocarcinoma. Eighty-one percent of the men had advanced Pca, 58% being metastatic disease. 48.1% had co-morbidities, 39.5% had hypertension, while 8.6% had both hypertension and diabetes. Comorbidities showed no correlation with PSA level (r=0.346), (p-value 0.375) and Gleason score (r=0.194), (p-value 0.639). Seventy-nine percent of the men had androgen deprivation therapy.

Conclusion: Most of the men presented with advanced disease, with all indices pointing towards lethal disease. The commonest co-morbidity was hypertension and co-morbidities had no relationship with the aggressiveness of prostate cancer. To ensure early presentation and prevent lethal forms of Pca, health education, screening, counselling for men in the high-risk group is paramount.

Keywords:
Prostate cancer, Gleason score, PSA, comorbidities, hypertension.

Article Details

How to Cite
Ofoha, C. G., & Magnus, F. E. (2019). Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria. Journal of Advances in Medicine and Medical Research, 31(5), 1-7. https://doi.org/10.9734/jammr/2019/v31i530297
Section
Original Research Article

References

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professional’s follow-up study. Int J Cancer. 2007;121(7):1571-1578.

Platz EA, Kantoff PW, Giovannucci E. Epidemiology of and risk factors for prostate cancer. Management of Prostate Cancer. 2000;19–45.

Miocinovic R. Epidemiology and risk factors. Management of Prostate Cancer. 2012;1–11.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J Cancer. 2010; 127(12):2893-2917.

Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int. J Urol. 2018;25(6):524-531.

Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness and mortality in men of African Descent. Prostate Cancer. 2013;1–12.

Chu LW, Ritchey J, Devesa SS, Quraishi SM, Zhang H, Hsing AW. Prostate cancer incidence rates in Africa. Prostate Cancer. 2011;1–6.

Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118(17): 4280–4289.

Matlaga BR, Eskew LA, Mccullough DL. Prostate biopsy: Indications and technique. Journal of Urol. 2003;169(1):12-9.

Streicher J, Meyerson BL, Karivedu V, Sidana A. A review of optimal prostate biopsy: Indications and techniques. Therapeutic Advances in Urology. SAGE Publications; 2019.

Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. The Lancet. 2003;361(9362):1045-1053.

Sternberg CN. What's new in the treatment of advanced prostate cancer? EJ Cancer. 2003;39(2):136-146.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.

Ajape AA, Ibrahim KO, Fakeye JA, Abiola OO. An overview of cancer of the prostate diagnosis and management in Nigeria: The experience in a Nigerian tertiary hospital. Ann Afr Med. 2010;9(3):113-117.

Ekeke ON, Amusan OE, Eke N. Management of prostate cancer in Port Harcourt, Nigeria: Changing Patterns. J WACS. 2012;1(3):58-77.

Leitzmann M, Rohrmann S. Risk factors for the onset of prostatic cancer: Age, location, and behavioural correlates. Clin Epidemiol. 2012;4:1-11.

Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43. populations worldwide: An analysis of time trends overall and by age group. IJC. 2015;138(6):1388-1400.

Bock CH, Peyser PA, Montie JE, Cooney KA. Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. The Prostate. 2005;64(1):60-66.

Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med. 2011; 5(4):515-526.

Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, et al. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011;5(6):416-421.

Bassey I-AE, Isiwele EM, Debua A. Prognostication studies of prostate cancer in Black Africa: Findings from Calabar, South-South, Nigeria. JCMR. 2018;5(5): E1-E5.

Saad F, Segal S, Eastham J. Prostate specific antigen kinetics and outcomes in patients with bone metastases from castration resistant prostate cancer treated with or without zoledronic acid. Eur Urol 2014;65(1):146-153.

Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077- 2085.

Ni C, Qiao Z. The evolving Gleason grading system. Chin J Cancer Res. 2016; 28(1):58-64.

Kryvenko ON, Epstein JI. Prostate cancer grading: A decade after the 2005 modified gleason grading system. APLM. 2016; 140(10):1140-1152.

Delahunt B, Lamb DS, Srigley JR, et al. Gleason scoring: A comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point. Pathology. 2010;42:339-343.

Kir G, Sarbay BC, Gümüş E, et al. The association of the cribriform pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract. 2014;210:640-644.

Obiorah C, Nwosu S. A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. NJCP. 2011;14(3):363-367.

Nwafor C, Keshinro O, Abudu E. A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience. NMJ. 2015;56(5):338-343.

Liang Z, Xie B, Li J, et al. Hypertension and risk of prostate cancer: A systematic review and meta-analysis. Sci Rep. 2016; 6:31358.

Di Francesco S, Tenaglia RL. Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis. Cent European J Urol. 2014;66(4):423-427.

Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: A meta-analysis. Springer Plus. 2016;5(1):1548.

Sapira M, Eke N, Nwofor A. Ethnicity and prostate cancer in Southern Nigeria: A preliminary report. Nig. J Surg. 2015;21(2): 96-101.

Jalloh M, Niang L, Ndoye M, Labou I, Gueye SM. Prostate cancer in Sub Saharan Africa. Journal of Nephrol Urol Research. 2013;1(1):15-20.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7-30.